Dr. Reddy’s expands commercial operations in Europe
The company launched select products in Italy and Spain, and is further strengthen its presence with the launch of anti-HIV products
April 18, 2017
By Kelsea Koh
Dr. Reddy’s Laboratories Ltd announced the expansion of its commercial operations in Europe with the introduction of its portfolio of generics in France. The first products will be made available in the hospital market in March 2017 in the area of oncology and anti-infectives, including antimycotics.
The company recently launched select products of its hospital portfolio in Italy and Spain, and is looking to further strengthen its presence in the two countries with the launch of anti-HIV products this year.
Abhijit Mukherjee, Chief Operating Officer, Dr. Reddy’s Laboratories said, “It is our constant endeavor to enhance the reach of our affordable and difficult-to-produce drugs. Our business expansion in Europe is a testimony to Dr. Reddy’s commitment to ensure access to affordable medicine for patients across the globe.”
With a diversified portfolio of injectables and complex generics, Dr. Reddy’s currently has two R&D centres, one manufacturing, and a packaging and storage facility in Europe.
About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe.